The HORIZON recurrent fracture trial evaluated the fracture recurrence and mortality in patients receiving zoledronic acid (Lyles et al 2007).
The HORIZON-Recurrent Fracture Trial (RFT) randomized men and women with a prior hip fracture to receive once yearly intravenous infusions of zoledronic acid.
34 The clinical efficacy of Zol in patients with a recent low-trauma hip fracture was investigated in a large randomized, double-blind, placebo-controlled, multicenter 5-year study, HORIZON-Recurrent Fracture Trial (RFT).
Furthermore, in the Cholesterol and Recurrent Events (CARE) trial, the relative efficacy of pravastatin in reducing events was greatest among those with elevated levels of hs-CRP.
In the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial [37], which evaluated clopidogrel in acute coronary syndromes, use of thrombolytic agents and glycoprotein IIb/IIIa inhibitors was slightly greater in the placebo group.
In the RE-SONATE (Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE) trial, investigators had to have equipoise regarding the need for continued anticoagulant therapy.
22 Similarly, no blood pressure lowering effect of pravastatin at doses capable of effectively improving the lipid profile was reported by a recent analysis of the Cholesterol and Recurrent Events (CARE) trial.
The final model included treatment group, sex, ECOG performance status, weight loss (characterised as ⩾5% or not, as in the E4599 trial), recurrent disease, presence of bone metastases, presence of liver metastases, presence of adrenal metastases, treatment-by-sex interaction and BSLD (all of which were significant at the 0.05 level).
4 5 However, dual antiplatelet treatment with aspirin and the P2Y12 inhibitor clopidogrel is recommended for 12 months in all patients with non-ST elevation acute coronary syndrome, as both patients who had revascularisation and those managed medically derived benefit in post hoc analyses from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial.
Previous studies investigating the cost of illness for ACS, however, have focused on data from the late 1990s or early 2000s, prior to the results of the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial for clopidogrel [ 9], as well as several versions of the ACC/AHA guidelines.
